Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose ...

Flagship Harbor Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) during the 4th quarter, ...

Exchange Traded Concepts LLC decreased its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 12.4% in the ...

When an employee in Jose Cepeda’s kitchen exhibited signs of extreme thirst and fatigue, the chef immediately recognized the ...

Beta Bionics hit net sales of $44.7m in the first nine months of 2024, marking an increase from $3.6m in 2023. Beta Bionics’ ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Healthcare costs in the U.S. continue to rise, making it difficult for millions of people to afford essential medical ...

The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via ... Libre 3 comes as rival real-time CGM player Dexcom received a European CE mark for its G7 device ...

KeyBanc highlighted WST, GXIG, and STVN as the main beneficiaries following robust demand in the Continuous Glucose ...

DexCom Inc. closed 38.30% below its 52-week high of $142.00, which the company achieved on March 26th.

DexCom Inc. closed 39.13% short of its 52-week high of $142.00, which the company achieved on March 26th.